Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
NCT06630624
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Liver Metastases
Liver Metastasis Colon Cancer
Interventions
DRUG:
IP-001
Sponsor
M.R. Meijerink
Collaborators
[object Object]
[object Object]